coronavirus
cov
affect
divers
group
anim
host
caus
plethora
diseas
anim
includ
progress
periton
acut
chronic
hepat
gastroenter
nephriti
enceph
human
coronaviru
infect
result
respiratori
tract
complic
vari
degre
sever
associ
gastroenter
four
human
coronavirus
hcov
endem
human
popul
mainli
associ
mild
selflimit
respiratori
ill
anoth
two
human
coronavirus
name
sever
acut
respiratori
syndrom
sar
cov
middl
east
respiratori
syndrom
mer
cov
caus
sever
respiratori
syndrom
present
signific
threat
high
fatal
rate
clinic
present
four
nonsever
endem
human
coronavirus
larg
indistinguish
symptomat
commonli
present
rhinorrhea
sore
throat
cough
fever
major
infect
associ
selflimit
upper
respiratori
tract
diseas
common
cold
also
present
high
morbid
outcom
lower
respiratori
tract
includ
bronchiol
pneumonia
asthmat
exacerb
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
croup
infect
patient
commonli
result
hospit
febril
seizur
report
human
coronavirus
signific
alarm
one
studi
indic
patient
infect
experi
febril
seizur
hcov
affect
age
group
elicit
seriou
diseas
young
elderli
immunocompromis
frequent
result
hospit
report
preval
hcov
associ
upper
lower
respiratori
tract
diseas
vari
rang
gener
public
seroconvert
toward
four
nonsever
hcov
primari
infect
shown
occur
childhood
reinfect
occur
throughout
life
given
high
preval
respiratori
infect
human
coronavirus
repres
substanti
diseas
burden
exacerb
high
implic
healthcar
worker
coronaviru
outbreak
outbreak
sarscov
merscov
less
year
later
highlight
addit
signific
threat
coronavirus
human
confirm
sar
outbreak
isol
incid
ever
increas
divers
anim
coronaviru
speci
especi
within
bat
likelihood
recombin
lead
futur
outbreak
high
threat
potenti
pandem
real
highli
pathogen
coronavirus
continu
spill
zoonot
sourc
human
popul
misdiagnosi
outbreak
pose
substanti
threat
healthcar
worker
nosocomi
spread
patient
put
pressur
alreadi
strain
healthcar
system
current
antivir
strategi
combat
infect
human
coronavirus
support
care
primari
treatment
regim
import
identifi
broad
spectrum
lead
compound
increas
proven
valuabl
target
drug
discoveri
effort
valid
effect
drug
target
sever
studi
even
term
achil
heel
coronavirus
wide
varieti
inhibitor
class
includ
peptidomimet
analogu
coval
inhibitor
small
molecul
inhibitor
assess
compound
identifi
ab
initio
structurebas
design
high
throughput
virtual
screen
inhibitor
either
target
enzym
activ
site
alloster
dimer
domain
first
gener
inhibitor
irrevers
peptidomimet
structur
often
five
residu
length
reactiv
warhead
terminu
form
coval
bond
thiolat
anion
catalyt
residu
reactiv
atom
warhead
reactiv
warhead
includ
michael
acceptor
aldehyd
epoxyketon
halomethyl
keton
trifluoromethyl
keton
peptid
deriv
warhead
inhibitor
later
follow
develop
nonpeptid
coval
inhibitor
use
coval
inhibitor
howev
limit
due
propens
offtarget
sideeffect
toxic
recent
studi
therefor
focus
develop
noncoval
inhibitor
gener
produc
larg
peptidomimet
compound
low
ligand
effici
current
still
effect
therapi
treatment
hcov
coronaviru
share
high
sequenc
homolog
well
main
chain
architectur
substrat
conserv
make
identif
broad
spectrum
lead
compound
viabl
substrat
bind
site
two
deepli
buri
subsit
well
shallow
subsit
vari
degre
solvent
exposur
substrat
specif
coronaviru
mainli
determin
posit
posit
absolut
specif
glutamin
stabil
subsit
via
hydrogen
bond
imidazol
van
der
waal
interact
surround
residu
pocket
site
prefer
leucin
methionin
fill
hydrophob
pocket
sidechain
site
solventexpos
therefor
site
expect
toler
wide
rang
function
show
prefer
basic
residu
sidechain
backbon
residu
surround
site
creat
highli
congest
pocket
favor
small
hydrophob
residu
posit
either
ser
thr
val
pro
subsit
also
accommod
small
residu
posit
may
includ
ser
ala
gli
typic
cleavag
recognit
site
therefor
ser
ala
val
thr
leuglu
ser
ala
gli
conserv
among
coronaviru
featur
therefor
exploit
design
potenti
broad
spectrum
lead
compound
crystal
structur
sarscov
obtain
pdb
obtain
homolog
model
vina
perform
initi
high
throughput
screen
drugsnow
dataset
zinc
compris
total
approxim
million
compound
ligand
file
obtain
sdf
format
convert
pdb
open
babel
ligand
pdb
file
convert
pdbqt
script
initi
virtual
screen
conduct
receptor
compris
largest
bind
pocket
therefor
identifi
largest
amount
primari
lead
bound
ligand
apo
structur
remov
creat
appropri
caviti
within
bind
site
dock
vina
receptor
process
autodock
tool
water
molecul
remov
polar
hydrogen
gasteig
charg
ad
histidin
proton
neutral
state
epsilon
nitrogen
accord
crystal
data
grid
box
search
center
activ
residu
grid
box
space
set
extend
grid
point
direct
encompass
entir
bind
pocket
top
rank
ligand
virtual
screen
form
primari
hitlist
accept
quantiti
medium
throughput
analysi
subsequ
refin
lowest
bind
score
within
hitlist
correspond
bind
affin
kcalmol
therefor
compound
equival
bind
affin
progress
dock
later
refin
glide
structur
prepar
maestro
protein
prepar
wizard
receptor
minim
restrain
minim
use
forc
field
heavi
atom
restrain
remain
within
origin
structur
defin
bind
site
dock
glide
structur
align
activ
inhibitor
obtain
crystal
structur
superimpos
activ
site
dock
glide
receptor
grid
gener
around
superimpos
ligand
accur
encompass
bind
pocket
grid
box
gener
direct
constraint
set
ligand
form
hydrogen
bond
pivot
residu
activ
pocket
set
remain
default
glide
receptor
grid
gener
glide
dock
perform
default
set
use
standard
precis
sp
mode
fulfil
previous
defin
constraint
ligand
fulfil
constraint
automat
exclud
bind
score
cutoff
defin
kcalmol
use
filter
hitlist
cutoff
predetermin
base
bind
affin
known
inhibitor
filter
compound
subsequ
import
gold
redock
structur
prepar
maestro
activ
site
defin
superimposit
activ
ligand
autom
dock
procedur
default
paramet
use
includ
dock
attempt
cluster
defin
heavi
atom
ligand
separ
rootmeansquar
deviat
rmsd
goldscor
fit
score
function
use
rank
ligand
base
goldscor
cutoff
ensur
accur
predict
bind
pose
rmsd
pose
predict
vina
glide
gold
measur
use
rmsdpi
script
ligand
rmsd
greater
predict
pose
exclud
primemmgbsa
method
use
calcul
bind
free
energi
ligand
within
dock
complex
pose
predict
glide
util
free
energi
bind
calcul
differ
minim
receptorinhibitor
complex
sum
energi
minim
unbound
inhibitor
receptor
ligand
pose
minim
use
local
optim
featur
prime
energi
complex
calcul
forc
field
gbsa
continuum
solvent
model
final
filter
bind
free
energi
cutoff
kcalmol
defin
determin
free
energi
bind
known
activ
inhibitor
pharmacophor
tool
molecular
oper
environ
moe
use
defin
pharmacophor
featur
use
ligand
structur
initi
high
throughput
virtual
screen
featur
includ
essenti
hydrogen
bond
residu
hydrophob
moieti
posit
exclud
volum
set
better
consid
steric
effect
nonessenti
featur
includ
hydrogen
bond
donor
acceptor
posit
hydrogen
bond
acceptor
pocket
singl
hydrogen
bond
donor
pocket
acceptor
pocket
total
four
pharmacophor
featur
requir
within
exclud
volum
pharmacophor
model
screen
drugsnow
dataset
ligand
satisfi
pharmacophor
queri
within
rmsd
proton
open
babel
steric
clash
caus
ligand
order
satisfi
pharmacophor
constraint
absenc
explicit
hydrogen
remov
refin
dock
glide
hydrogen
bond
constraint
use
primari
filter
compound
immedi
assess
mmgbsa
score
function
avoid
possibl
fals
neg
less
reliabl
dock
score
function
previous
describ
mmgbsa
cutoff
kcalmol
implement
mention
techniqu
conduct
high
throughput
virtual
screen
zinc
drugsnow
dataset
dock
pharmacophor
model
structurebas
screen
identifi
potenti
binder
ligandbas
approach
focus
identifi
compound
would
potenti
form
broad
spectrum
inhibitor
remain
three
structur
incorpor
studi
five
structur
align
ligand
identifi
dock
pharmacophor
model
superimpos
individu
activ
site
side
chain
residu
activ
pocket
assum
orient
result
steric
clash
ligand
refin
ligand
minim
prime
better
fit
pocket
mmgbsa
method
describ
previous
appli
predict
free
bind
energi
complex
bind
energi
kcalmol
use
cutoff
hydrogen
bond
constraint
pocket
appli
discrimin
potenti
binder
nonbind
effort
miss
potenti
lead
interpret
certain
paramet
left
flexibl
paramet
support
advanc
compound
atom
forc
field
assign
receptor
structur
use
three
point
water
model
input
hydrogen
coordin
file
ignor
assign
accord
forc
field
histidin
proton
state
assign
epsilon
nitrogen
neutral
form
accord
crystallograph
data
ligand
pose
predict
molecular
dock
prepar
swisparam
proteinligand
complex
place
center
solvat
cubic
box
nm
box
edg
system
solvat
water
model
sodium
counter
ion
ad
neutral
system
system
energi
minim
brief
dynam
simul
use
steepest
descent
minim
steepest
descent
converg
fmax
long
rang
electrostat
interact
calcul
particl
mesh
ewald
pme
method
cutoff
nm
period
boundari
condit
appli
nvt
npt
equilibr
run
step
ps
use
fs
time
step
leapfrog
integr
bond
constrain
linc
algorithm
pme
use
long
rang
electrostat
fourier
space
short
rang
electrostat
van
der
waal
cutoff
nm
nm
respect
coordin
veloc
energi
save
everi
ps
nvt
equilibr
temperatur
coupl
achiev
vrescal
algorithm
target
temperatur
k
pressur
coupl
npt
equilibr
achiev
via
parrinellorahman
algorithm
incorpor
npt
equilibr
temperatur
stabl
ensur
proper
densiti
reach
approxim
follow
nvt
npt
system
equilibr
unrestrain
ns
simul
step
run
leap
frog
integr
save
coordin
veloc
energi
everi
ps
paramet
maintain
nvt
npt
equilibr
includ
temperatur
pressur
coupl
previous
solv
complex
inhibitor
xray
crystallographi
high
resolut
correspond
crystallograph
structur
protein
data
bank
pdb
code
show
dimer
structur
inhibitor
zinc
nethylnphenyldithiocarbam
epdtc
coordin
catalyt
dyad
residu
zinccent
tetrahedr
geometri
apo
form
solv
dimer
form
xray
crystallographi
high
resolut
respect
pdb
code
structur
howev
remain
unpublish
academ
journal
recent
group
solv
publish
structur
homolog
model
pdb
code
repres
structur
previous
solv
xray
crystallographi
resolut
complex
peptidomimet
coval
inhibitor
pdb
entri
contain
total
four
chain
two
chain
form
activ
dimer
structur
remain
two
found
monomer
form
chain
contain
coval
inhibitor
bound
activ
site
undergo
nucleophil
attack
activ
cystein
form
irrevers
coval
bond
inhibitor
possess
sever
pharmacophor
featur
common
natur
substrat
favor
drug
develop
util
develop
pharmacophor
model
virtual
screen
sever
structur
avail
repres
sarscov
howev
major
includ
structur
complex
peptidomimet
coval
inhibitor
mutat
studi
time
studi
commenc
one
structur
could
identifi
complex
small
molecul
inhibitor
structur
pdb
code
also
repres
coronaviru
noncoval
inhibitor
structur
could
use
necessari
benchmark
latter
studi
chosen
repres
sarscov
crystallograph
structur
contain
noncoval
furyl
amid
ligand
identifi
high
throughput
screen
subsequ
lead
optim
base
structureact
relationship
within
bind
pocket
molecular
dock
algorithm
often
calibr
train
set
experiment
ligandprotein
complex
accuraci
dock
program
often
highli
depend
train
set
use
highlight
import
confirm
dock
softwar
use
virtual
screen
capabl
replic
bind
mode
known
experiment
inhibitor
class
enzym
studi
order
confirm
molecular
dock
algorithm
use
studi
well
suit
human
coronavirus
relat
class
previous
solv
experiment
structur
bound
noncoval
inhibitor
requir
accur
replic
experiment
bind
pose
molecular
dock
confirm
suitabl
dock
algorithm
virtual
screen
initi
studi
structurebas
design
inhibitor
target
coronavirus
focus
peptidomimet
compound
reactiv
warhead
group
form
irrevers
coval
interact
activ
cy
residu
larg
coval
inhibitor
would
incompat
molecular
dock
replic
quantum
mechan
necessari
coval
bond
format
outsid
capabl
molecular
dock
pdb
sever
experiment
structur
variou
speci
coronavirus
bound
inhibitor
could
identifi
almost
structur
repres
larg
peptidomimet
coval
inhibitor
except
structur
repres
noncoval
inhibitor
modest
size
could
identifi
pdb
replic
bind
mode
bound
inhibitor
dock
algorithm
use
virtual
screen
subsequ
refin
process
would
indic
well
calibr
class
receptor
default
paramet
appli
high
throughput
virtual
screen
vina
refin
glide
appli
inhibitor
receptor
rmsd
heavi
atom
exclud
hydrogen
experiment
structur
predict
pose
dock
welldefin
benchmark
assess
accuraci
molecular
dock
sampl
algorithm
figur
repres
experiment
pose
ligand
overlaid
predict
pose
vina
glide
vina
abl
accur
predict
pose
top
rank
pose
within
rmsd
experiment
structur
within
pocket
figur
orient
furan
somewhat
distort
conform
ring
structur
assum
orient
right
angl
experiment
pose
overal
predict
pose
vina
correspond
experiment
pose
high
level
accuraci
glide
also
capabl
accur
predict
pose
within
pocket
within
rmsd
figur
indic
sampl
vina
glide
well
calibr
class
enzym
studi
remain
structur
highli
homolog
achiev
equival
level
accuraci
result
strongli
support
use
vina
high
throughput
tool
virtual
screen
indic
use
glide
subsequ
refin
tool
accuraci
predict
bind
pose
novel
ligand
high
lead
compound
also
provid
mean
set
benchmark
score
function
free
energi
bind
estim
inhibitor
achiev
bind
affin
estim
kcalmol
bound
effort
reduc
number
fals
neg
valu
decreas
kcalmol
filter
purpos
mmgbsa
score
advis
threshold
valu
defin
experiment
structur
highli
homolog
structur
known
activ
inhibitor
therefor
score
mmgbsa
free
energi
bind
ligand
strain
taken
account
equal
kcalmol
ligand
highli
suit
toward
structur
goal
identif
broad
spectrum
inhibitor
cutoff
valu
decreas
kcalmol
done
ensur
ligand
potenti
broad
spectrum
activ
miss
base
predict
inabl
bind
singl
receptor
vina
chosen
tool
conduct
initi
high
throughput
screen
approxim
million
compound
drugsnow
dataset
zinc
databas
initi
screen
select
receptor
identifi
highli
refin
subset
potenti
inhibitor
receptor
possess
largest
bind
pocket
structur
analyz
sitemap
data
shown
therefor
propos
provid
largest
number
initi
hit
compound
primari
hitlist
consist
top
rank
compound
high
throughput
virtual
screen
htv
zinc
drugsnow
dataset
conduct
vina
quantiti
refin
analysi
would
achiev
rank
initi
virtual
screen
base
dock
score
alon
serv
start
point
select
criteria
assum
predict
bind
affin
somewhat
reflect
true
bind
affin
lowest
bind
score
within
hitlist
correspond
kcalmol
score
function
shown
success
differenti
binder
nonbind
rank
bind
score
reason
ligand
achiev
score
also
includ
studi
yield
total
hit
compound
assess
refin
initi
hitlist
ligand
conduct
redock
glide
gold
score
respect
score
function
mmgbsa
improv
likelihood
identifi
actual
activ
compound
three
sampl
algorithm
four
score
function
appli
hitlist
identifi
vina
consensu
base
approach
approach
frequent
improv
enrich
rate
activ
compound
virtual
screen
context
comparison
use
singl
algorithm
dock
score
initi
stage
refin
includ
redock
glide
standard
precis
rescor
intern
glide
gscore
score
function
order
defin
threshold
bind
score
cutoff
prefilt
hit
crystallograph
structur
bound
inhibitor
use
score
function
compar
structur
import
defin
bind
score
cutoff
base
relat
experiment
structur
inhibitor
achiev
bind
affin
estim
kcalmol
bound
effort
reduc
number
fals
neg
valu
decreas
kcalmol
subsequ
stage
hitlist
refin
identifi
hit
compound
receptor
directli
import
gold
redock
rescor
goldscor
fit
cutoff
defin
use
prefilt
hit
stage
hitlist
refin
point
bind
pose
hit
could
analyz
manual
inspect
natur
substrat
form
hydrogen
bond
pocket
pocket
fill
hydrophob
moieti
ligand
therefor
assess
pose
filter
script
manual
maestro
confirm
ligand
identifi
hitlist
met
pharmacophor
constraint
comprehens
filter
three
sampl
score
algorithm
pharmacophor
featur
constraint
provid
us
highli
defin
hitlist
compound
assess
free
energi
bind
highli
advanc
mmgbsa
score
function
would
provid
confid
hit
identifi
fact
repres
highlikelihood
activ
compound
rescor
final
hitlist
mmgbsa
identifi
total
ligand
pass
filter
pharmacophor
constraint
receptor
includ
total
three
sampl
algorithm
four
score
function
vina
glide
gold
highli
advanc
mmgbsa
respect
two
pharmacophor
constraint
hydrogen
bond
acceptor
pocket
hydrophob
moieti
fill
pocket
consensu
dock
score
approach
comparison
sever
studi
identifi
novel
lead
compound
virtual
screen
singl
molecular
dock
algorithm
incorpor
comprehens
list
techniqu
use
studi
heighten
probabl
ligand
identifi
final
hitlist
repres
novel
scaffold
activ
molecul
high
homolog
variou
human
coronavirus
compound
exhibit
high
potenti
broad
spectrum
effect
vari
techniqu
drug
design
led
identif
differ
ligand
dataset
even
identif
diverg
scaffold
use
multipl
techniqu
therefor
improv
probabl
identifi
divers
set
lead
compound
pharmacophor
model
base
larg
singl
coval
inhibitor
inhibitor
chosen
possess
sever
favor
noncoval
featur
gener
pharmacophor
model
gener
practic
sever
inhibitor
often
use
gener
pharmacophor
model
featur
frequent
repeat
includ
pharmacophor
featur
well
document
presenc
sever
activ
ligand
would
serv
replic
prior
knowledg
essenti
featur
pharmacophor
model
includ
hydrogen
bond
acceptor
posit
hydrophob
moieti
posit
nonessenti
featur
includ
hydrogen
bond
donor
acceptor
posit
interact
hydrogen
bond
acceptor
pocket
singl
hydrogen
bond
donor
pocket
acceptor
pocket
total
four
featur
includ
two
essenti
featur
two
nonessenti
featur
within
exclud
volum
requir
potenti
hit
satisfi
pharmacophor
model
molecular
oper
environ
moe
use
gener
pharmacophor
model
conduct
virtual
screen
entir
zinc
drugsnow
dataset
ensur
primari
hitlist
manag
size
ligand
satisfi
pharmacophor
within
rmsd
filter
initi
hitlist
includ
approxim
compound
sinc
moe
util
unit
atom
forc
field
necessari
add
hydrogen
open
babel
proton
ligand
gener
sever
steric
clash
within
activ
pocket
refineonli
dock
glide
therefor
use
remov
clash
pharmacophor
model
filter
compound
base
presenc
hydrogen
bond
acceptor
posit
take
account
distanc
geometri
essenti
format
hydrogen
bond
pose
filter
script
use
refin
hitlist
contain
hit
score
hitlist
mmgbsa
reduc
size
compound
previous
defin
cutoff
valu
two
virtual
screen
approach
includ
molecular
dock
pharmacophor
model
activ
inhibitor
provid
us
hit
respect
initi
attempt
redock
hit
individu
bind
pocket
remain
four
structur
order
identifi
potenti
broad
spectrum
inhibitor
prove
highli
unsuccess
neither
bind
mode
bind
affin
free
energi
bind
could
replic
complex
studi
find
contradict
hypothesi
high
degre
homolog
variou
activ
site
allow
develop
broad
spectrum
inhibitor
static
natur
receptor
dock
allow
degre
inducedfit
phenomena
commonli
observ
ligand
substrat
bind
although
residu
within
activ
site
individu
highli
homolog
orient
sidechain
variabl
structur
hinder
ligand
bind
dynam
physiolog
system
sidechain
would
accommod
ligand
bind
inducedfit
phenomena
howev
molecular
dock
process
circumv
static
natur
receptor
sole
reason
inabl
replic
bind
mode
seen
remain
structur
orient
residu
sidechain
insert
activ
pocket
highli
variabl
inabl
replic
dynam
movement
sidechain
dock
led
highli
variabl
ineffici
bind
mode
decreas
bind
affin
overcom
short
fall
molecular
dock
receptor
align
ligand
superimpos
individu
activ
site
use
coordin
identifi
dock
refineonli
dock
residu
sidechain
result
steric
clash
ligand
refin
use
prime
modul
replic
dynam
flexibl
movement
allow
sidechain
accommod
ligand
pocket
ligand
minim
within
pocket
remov
steric
clash
bind
mode
predict
use
approach
assess
use
pharmacophor
constraint
hydrogen
bond
hydrophob
moieti
pocket
score
mmgbsa
cutoff
previous
defin
implement
compound
identifi
hitlist
potenti
binder
compound
could
replic
interact
pocket
fulfil
mmgbsa
cutoff
tabl
four
compound
identifi
pharmacophor
model
could
fulfil
requir
tabl
final
list
ligand
repres
distinct
cluster
figur
free
energi
bind
known
activ
inhibitor
respect
coronaviru
also
shown
tabl
tabl
compar
purpos
conform
ligand
identifi
molecular
dock
result
indic
bind
activ
site
form
similar
key
interact
throughout
five
proteas
studi
pyridin
fill
pocket
form
hydrogen
bond
pyridin
nitrogen
imidazol
form
linker
center
structur
mediat
format
hydrogen
bond
backbon
form
third
hydrogen
bond
via
backbon
carbonyl
ligand
nh
exhibit
fourth
hydrogen
bond
residu
conserv
structur
howev
orient
toward
solvent
expos
exterior
pocket
posit
gln
replac
therefor
contribut
format
bond
two
ring
also
fill
hydrophob
pocket
figur
molecular
dynam
studi
indic
interact
highli
conserv
form
averag
three
bond
simul
high
occup
bond
remain
four
structur
exhibit
similar
profil
howev
vari
degre
occup
averag
bond
format
structur
display
high
occup
posit
howev
decreas
occup
posit
observ
lowest
occup
respect
display
moder
occup
respect
loss
hydrogen
bond
format
posit
often
caus
pyridin
ring
orient
right
angl
except
structur
also
form
hydrogen
bond
moder
frequenc
bond
predominantli
form
via
backbon
howev
capabl
form
backbon
sidechain
sidechain
exhibit
higher
frequenc
bond
form
seen
dock
result
exhibit
rel
low
occup
indic
result
achiev
molecular
dynam
rel
strong
agreement
molecular
dock
bond
form
high
frequenc
except
bond
pyridin
n
remain
present
howev
lower
occup
compound
howev
still
provid
excel
scaffold
lead
optim
substructur
fill
subsit
make
extens
stabl
interact
surround
residu
includ
two
hydrogen
bond
central
nh
backbon
lead
optim
may
explor
replac
pyridin
ring
relat
lactam
ring
known
mediat
two
hydrogen
bond
one
ligand
carbonyl
second
hydrogen
bond
lactam
nh
presenc
second
hydrogen
bond
van
der
waal
interact
mediat
via
ring
substitu
may
stabil
compound
within
pocket
phenylalanin
substitu
imidazol
ring
also
shown
improv
inhibitori
effect
peptidomimet
inhibitor
analysi
ligand
rmsd
indic
structur
deviat
extent
start
structur
begin
simul
posit
stabl
minor
fluctuat
observ
point
solvent
access
surfac
area
ligand
also
remain
consist
throughout
durat
simul
fluctuat
within
rang
figur
assess
ligand
radiu
gyrat
also
indic
compact
ligand
alter
greatli
ns
simul
fluctuat
within
structur
indic
ligand
stabl
within
pocket
dissoci
surround
solvent
structur
bound
inhibitor
identifi
pharmacophor
model
indic
conserv
interact
receptor
ligand
previou
compound
pyridin
ring
fill
pocket
form
hydrogen
bond
imidazol
backbon
carbonyl
form
hydrogen
bond
ligand
nh
residu
replac
gln
remain
structur
howev
backbon
carbonyl
two
residu
perfectli
align
therebi
allow
format
hydrogen
bond
structur
backbon
nh
form
hydrogen
bond
ligand
carbonyl
fourth
hydrogen
bond
observ
sidechain
ligand
carbonyl
posit
gln
align
structur
structur
superimposit
show
pro
posit
account
loss
hydrogen
bond
two
methyl
group
insert
deep
pocket
made
extens
hydrophob
interact
surround
residu
potenti
problemat
featur
ligand
solvent
expos
made
interact
surround
residu
lead
optim
step
may
explor
remov
substitu
ascertain
structureact
relationship
figur
molecular
dynam
trajectori
show
strong
correl
seen
pharmacophor
model
except
complex
structur
pyridin
ring
gradual
dissoci
pocket
around
ns
follow
almost
complet
dissoci
ligand
activ
site
becam
complet
solvent
expos
two
methyl
group
fill
hydrophob
pocket
remain
substructur
ligand
maintain
structur
conform
activ
subsit
indic
import
group
ligand
stabil
orient
subsit
residu
includ
remain
unalt
therefor
could
attribut
loss
stabil
movement
may
like
attribut
initi
minor
loss
stabil
caus
movement
closer
pyridin
ring
subsequ
bond
format
ala
backbon
pyridin
n
movement
destabil
pyridin
ring
subsequ
form
new
hydrogen
bond
point
pyridin
almost
complet
lost
orient
pocket
result
loss
van
der
waal
interact
lead
complet
dissoci
pocket
figur
movement
also
correspond
gradual
increas
rmsd
assum
stabl
conform
indic
unstabl
ligand
posit
transform
ser
suggest
hydrophob
sidechain
ala
may
promot
movement
toward
pyridin
encourag
rotat
nitrogen
toward
ala
backbon
orient
pyridin
ring
somewhat
stabil
bifurc
interact
sidechain
promot
movement
pyridin
n
away
without
disrupt
interact
lead
optim
step
may
therefor
preferenti
incorpor
core
structur
prevent
rotat
pyridin
result
steric
clash
mention
previous
explor
phenylalanin
substitu
imidazol
lactam
ring
posit
may
also
contribut
posit
stabil
ligand
within
pocket
remain
structur
howev
show
stabil
ligand
within
activ
pocket
occup
hydrogen
bond
rang
interact
also
highli
conserv
frequenc
posit
occupi
gln
remain
structur
show
vari
degre
bond
format
presenc
result
signific
reduct
bond
format
gln
show
moder
high
occup
occup
sidechain
shown
form
hydrogen
bond
ligand
howev
residu
highli
solvent
expos
therefor
result
high
degre
flexibl
sidechain
hinder
format
bond
observ
frequenc
bond
format
respect
ligand
howev
abl
stabil
sidechain
maintain
format
bond
high
degre
frequenc
ligand
rmsd
show
similar
profil
previous
describ
complex
initi
larg
movement
observ
follow
subsequ
stabil
ligand
within
activ
site
structur
includ
observ
signific
fluctuat
within
stabl
conform
larg
attribut
presenc
solvent
expos
dioxolan
moieti
featur
interact
stabil
within
pocket
structur
contribut
interact
futur
studi
may
explor
remov
substitu
ascertain
effect
stabil
radiu
gyrat
confirm
rmsd
result
structur
fluctuat
except
deter
greatli
approxim
ns
signifi
point
pyridin
ring
complet
dissoci
pocket
howev
result
increas
solvent
access
surfac
area
structur
fluctuat
except
structur
confirm
great
confid
interact
conform
observ
within
rigid
pharmacophor
model
repres
ligand
identifi
molecular
dock
also
abl
larg
fulfil
interact
orient
observ
lead
compound
shown
promis
potenti
inhibitor
coronavirus
larg
repres
peptidomimet
compound
coval
alter
thiolat
anion
activ
cy
residu
compound
gener
larg
high
likelihood
target
effect
coval
modif
yet
remain
commerci
avail
molecular
entiti
treatment
coronavirus
studi
focus
develop
broad
spectrum
noncoval
inhibitor
knowledg
none
aim
priorit
identif
broad
spectrum
lead
compound
inhibit
relat
coronavirus
frequent
affect
human
name
reason
insuffici
knowledg
surround
structur
broad
spectrum
inhibitor
target
famili
proteas
studi
focus
coronaviru
associ
sar
provid
valuabl
insight
structur
ligand
scaffold
potenti
noncoval
inhibitor
differ
techniqu
use
virtual
screen
led
identif
divers
set
lead
compound
one
techniqu
abl
identifi
compound
may
miss
reason
use
joint
dock
pharmacophor
model
base
virtual
screen
strategi
identifi
highli
defin
list
potenti
lead
compound
molecular
dock
pharmacophor
model
extrem
use
tool
design
identif
novel
lead
compound
rel
low
infrastructur
fiscal
depend
import
pharmaceut
industri
overlook
even
though
sever
shortcom
fundament
flaw
structurebas
techniqu
includ
static
natur
receptor
implicit
solvent
model
use
virtual
screen
molecular
dynam
advanc
silico
tool
allow
us
fill
void
incorpor
newtonian
physic
simul
dynam
movement
protein
explicit
solvent
model
therebi
replic
nativ
environ
protein
molecular
dynam
simul
also
provid
mechanist
explan
ligand
inact
would
imposs
identifi
vitro
techniqu
studi
identifi
key
featur
respons
destabil
ligand
within
bind
pocket
therebi
allow
us
identifi
substitu
replac
round
lead
optim
ligand
inact
may
result
singl
misplac
substitu
mechanist
view
point
provid
extens
inform
futur
lead
optim
essenti
pharmacophor
constraint
includ
acceptor
hydrophob
moieti
use
dock
pharmacophor
model
drug
discoveri
method
would
expect
gener
hitlist
similar
scaffold
final
hitlist
contain
total
ligand
molecular
dock
four
identifi
pharmacophor
model
howev
highli
diverg
repres
distinct
cluster
determin
use
pubchem
http
pubchemncbinlmnihgov
structur
cluster
webservic
shape
featur
similar
recommend
paramet
achiev
statist
signific
confid
interv
figur
similar
calcul
use
shapeonli
featureonli
yield
similar
result
data
shown
cluster
member
alreadi
preselect
featur
fill
pocket
similar
estim
bind
affin
structur
cluster
significantli
dissimilar
repres
valuabl
scaffold
experiment
valid
use
basi
futur
lead
optim
anticoronavir
inhibitor
discoveri
experi
simul
potenti
inhibitor
previous
identifi
structur
ligandbas
drug
design
techniqu
includ
molecular
dock
pharmacophor
model
could
larg
replic
interact
observ
static
model
pyridin
ring
fill
pocket
stabl
model
ligandprotein
complex
known
inhibitor
evid
featur
contribut
posit
antivir
effect
inhibitor
howev
remain
sever
complex
show
instabl
pyridin
ring
within
pocket
therefor
propos
futur
lead
optim
explor
effect
incorpor
lactam
ring
posit
known
better
replic
interact
natur
substrat
also
effect
sarscov
phenylalanin
substitu
imidazol
ring
also
shown
efficaci
posit
replic
major
interact
observ
static
structurebas
model
molecular
dock
pharmacophor
model
suggest
structurebas
techniqu
correct
identifi
key
interact
orient
ligand
within
pocket
therefor
confid
assum
remain
ligand
identifi
structurebas
techniqu
fact
correct
conform
repres
promis
lead
compound
second
gener
lead
discoveri
focus
nonpeptid
noncoval
inhibitor
still
larg
infanc
futur
vitro
activ
assay
ligand
identifi
studi
provid
vital
inform
novel
scaffold
lead
optim
divers
comprehens
approach
hitlist
refin
also
ensur
high
likelihood
presenc
bioactiv
within
list
studi
provid
promis
start
pursuit
activ
lead
compound
broad
spectrum
inhibit
associ
human
coronavirus
result
strongli
support
vitro
test
highli
refin
hitlist
activ
data
provid
valuabl
inform
structur
bioactiv
scaffold
could
repres
next
gener
small
lead
molecul
conclus
drugdesign
sphere
varieti
comput
approach
use
variou
stage
drugdesign
process
support
experiment
techniqu
structurebas
ligandbas
drug
design
approach
develop
valuabl
drug
discoveri
tool
owe
versatil
synergist
charact
importantli
howev
predict
virtual
screen
method
meant
replac
experiment
affin
determin
complement
experiment
method
produc
enrich
subset
larg
chemic
databas
increas
possibl
compound
actual
bind
drug
target
interest
therefor
sinc
past
research
shown
mani
predict
drug
candid
fail
prove
effect
vivo
experiment
valid
identifi
ligand
report
manuscript
essenti
